Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Teclistamab, Other BCMA-Targeted Agents Represent New Options in Relapsed/Refractory Myeloma

April 1st 2023

Andrew Kin, MD, expands on the ways BCMA-targeted therapies that are currently available and under development have shifted the treatment landscape for relapsed/refractory multiple myeloma, the implications of the approval of teclistamab, and the limitations that still exist for using BCMA-targeted agents.

Dr Kin on the Limitations of BCMA-Targeted Therapies in Myeloma

March 30th 2023

Andrew Kin, MD, discusses the limitations and unmet needs associated with the use of BCMA-targeted therapies in relapsed/refractory multiple myeloma.

Dr Kin on the Withdrawal of Belantamab Mafodotin in R/R Multiple Myeloma

March 27th 2023

Andrew Kin, MD, discusses the withdrawal of the United States marketing authorization of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma

March 24th 2023

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

Dr Zonder on CAR T-cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Myeloma

March 23rd 2023

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Callander on Early CAR T-cell Therapy Referrals in Multiple Myeloma

March 23rd 2023

Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.

Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

March 22nd 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

March 22nd 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Dr. Godara on Approved CAR T-cell Therapies in Multiple Myeloma

March 21st 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

The FDA has granted an orphan drug designation to ISB 1442, the first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Brunner on the Use of CAR T-cell Therapy to Improve Post-ASCT Responses in Multiple Myeloma

March 20th 2023

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Dr. Brunner on the Utilization of Advanced Imaging Modalities in R/R Multiple Myeloma

March 17th 2023

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

March 15th 2023

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Dr. Richardson on Proteasome Inhibitor/Monoclonal Antibody Combinations in Myeloma

March 14th 2023

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Dr. Godara on Treatment Strategies Following First Relapse in Multiple Myeloma

March 8th 2023

Amandeep Godara, MBBS, discusses the current treatment strategies following first relapse for patients with multiple myeloma.

Dr. Giralt on the Rationale of the Karmma-3 trial of Ide-cel in R/R Myeloma

March 6th 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.